NCT00386802已完成4 期
ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.
PETHEMA Foundation13 个研究点 分布在 1 个国家目标入组 115 人开始时间: 2006年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 115
- 试验地点
- 13
- 主要终点
- Frequency of use of broad-spectrum antifungals in the episode of neutropenia.
研究概览
简要总结
Primary purpose: Frequency of use of broad-spectrum antifungals in the episode of neutropenia.
Secondary purposes:To determine the safety and toxicity measure by:
- Frequency of Invader Fungal Infection.
- Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study.
- Mortality
- Development of nephrotoxicity
- Use of galactomannan in this clinical context
- Time of administration of empirical antifungal therapy of broad-spectrum.
详细描述
Clinical trial with a pharmaceutical speciality in the conditions of authorized use
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult and pediatric patients (from 2 years old on) with diagnostic of hematologic malignancies or solid tumour.
- •Patients who will develop neutropenia (<500PN) post chemotherapy or post Bone Marrow Transplantation (BMT) that according to the center, they can receive empirical antifungal treatment of broad-spectrum.
- •Controlled patients with galactomannan in blood twice weekly.
- •Empirical antibacterial therapy of broad-spectrum, as possible the Pethema protocol that it is activated in this moment. Also it will be validated the monotherapy with carbapenemic or cephalosporin of fourth or third generation, or the biotherapy.
- •Inclusion of patient since the start of his chemotherapy or therapy of preparation.
- •If a bacterial infection is documented, it will be treated and controlled before to begin the empirical antifungal treatment.
- •Signed of informed consent.
- •Negative pregnancy test in fertile patients
排除标准
- •Use of antifungal prophylaxis with triazoles with activity against Aspergillus, or use of others systematics antifungal by previous Invader Fungal Infection or other reasons.
- •Use prophylactic of fluconazole to dose higher than 100 mg/day.
- •Allergy to azoles
- •To have a invader fungal infection at start of episode of neutropenia with fever.
- •High effect in the unity of insulation of Candida strong to fluconazole that to opinion of center it hasn´t appropriate to include in a protocol where it is considered the use of empirical fluconazole.
- •Neutropenias made by aplastic anemia or other faults of bone similar.
- •Inclusion previous in this study.
- •The patients will be excluded if they have settled by Aspergillus, C.krusei or C.gladiata in this episode of neutropenia, or in other and if they lack of the results of the cultures of vigilance in the present episode. If it presents positive result for any of those pathogens the empirical treatment will must be with a antifungal that it covers good (amphotericin, caspofungin or voriconazole) and not with fluconazole, then those patients will not follow this protocol.
- •To receive drugs, which aren´t indicated in patients in treatment with voriconazole and/or with fluconazole.
- •The patients will not be excluded if they receive antibacterial prophylaxis oral with quinolones, macrolides, etc., or stimulating factors G-CSF, GM-CSF or similar.
- •Cause of exclusion will be the fault of fulfilment of inclusion criteria. Above all the patients will be excluded if they:
- •have fault of twice weekly monitoring with galactomannan.
- •have a bacterial infection not very good treated and controlled before to can begin the empirical antifungal infection (according to definition previous)
- •have at final, a neutropenia of short stay that it has a risk important of Invader Fungal Infection. This data naturally will not know in the moment of include at patient in the study. It defines as neutropenia of short stay if it last out less of 5 days.
结局指标
主要结局
Frequency of use of broad-spectrum antifungals in the episode of neutropenia.
时间窗: 2 years
次要结局
- To determine the safety and toxicity measure by:(1 year)
- Frequency of Invader Fungal Infection.(2 years)
- Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study.(2 years)
- Mortality(2 years)
- Development of nephrotoxicity(2 years)
- Use of galactomannan in this clinical context(2 years)
- Time of administration of empirical antifungal therapy of broad-spectrum.(6 months)
研究者
研究点 (13)
Loading locations...
相似试验
终止
4 期
Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged NeutropeniaMalignant HemopathyDuration of Neutropenia Following Chemotherapy > 10 DaysNCT00190463Assistance Publique - Hôpitaux de Paris300
招募中
不适用
A study to desribe usage of antifungal drugs in Selected Clinical Care Settings of a Tertiary Care Teaching HospitalCTRI/2018/05/013733KEM Hospital
已完成
不适用
Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and NeutropeniaFebrile NeutropeniaNCT00723073Brigham and Women's Hospital323
已完成
不适用
Clinical investigation of anti-fungal strategies in patients under aggressive treatment of hematological malignanciesAspergillosisZ94.80B44C92D46.9Myeloid leukaemiaMyelodysplastic syndrome, unspecifiedDRKS00000347niklinik Freiburg Häm/Onk220
已完成
4 期
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal InfectionInvasive Fungal InfectionNCT01198236Zhejiang University150